Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. - Gorodnova TV; Sokolenko AP; Kotiv KB; Sokolova TN; Ivantsov AO; Guseynov KD; Nekrasova EA; Smirnova OA; Berlev IV; Imyanitov EN (Hereditary cancer in clinical practice, 2021)